CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 42 enrolled
Drug / intervention
RAS prostatectomy and RAS cholecystectomydevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05715827
NCT05715827N/ACompleted

A Prospective, Single-center, Single-arm, Pivotal Trial to Evaluate Safety and Efficacy of the Medtronic Hugo™ Robotic Assisted Surgery (RAS) System (Hello Hugo)

Medtronic - MITG·interventional·Posted Feb 8, 2023·Updated Nov 5, 2024

In Brief

A clinical study evaluating RAS prostatectomy and RAS cholecystectomy for Prostate Cancer and 3 related conditions. Completed, enrolled 42 participants across 1 site.

Detailed Summary

The goal of this clinical trial is to test the safety and effectiveness of the Medtronic Hugo™ RAS System in patients undergoing a prostatectomy or a cholecystectomy. A minimum of 40 subjects will be enrolled at single site in Republic of Korea: 20 for prostatectomy and 20 for cholecystectomy. All participants will be followed for 30 days (±7 days) post-procedure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedFeb 8, 2023
Enrollment StartFeb 12, 2023
Primary CompletionJun 5, 2023
Study CompletionJul 10, 2023
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 3.4 years ago

Interventions

RAS prostatectomy and RAS cholecystectomydevice

There are two types of interventions in the study. Patients indicated for Robotic Assisted Surgery (RAS) for a prostatectomy will have the RAS surgery using the Medtronic Hugo RAS system. Patients indicated for Robotic Assisted Surgery (RAS) for a cholecystectomy will have the RAS surgery using the Medtronic Hugo RAS system.